HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $660

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $600 to $660.